Objectives-To compare echocardiographic findings in patients with critical aortic stenosis following surgical (SAVR) or transcatheter aortic valve replacement (TAVR Background-The Placement of Aortic Transcatheter Valves trial randomized patients 1:1 to SAVR or TAVR Methods-Echocardiograms were obtained at baseline, discharge, 30 days, 6 months, 1 year, and 2 years post procedure and analyzed in a core laboratory. For the analysis of post-implant variables, the first interpretable study (≤ 6 mos) was used.
Introduction
Transcatheter aortic valve replacement (TAVR) has emerged as a reasonable alternative to surgical aortic valve replacement (SAVR) (1) (2) (3) (4) (5) . The Placement of Aortic Transcatheter Valves (Partner) trial was the first randomized trial comparing TAVR to standard-of-care therapies in a rigorous fashion. Two-year clinical outcomes in high risk, operable patients with severe aortic stenosis (Partner Cohort A) showed TAVR was non-inferior to SAVR without significant differences in all-cause mortality or cardiovascular mortality or evidence for structural valve failure.
Echocardiography is the recommended imaging modality for the assessment of aortic valve stenosis and prosthetic valve function (6) (7) (8) and was used for patient selection, valve sizing, and extended follow up (1, 2) . In contrast to previous reports relying on site interpretations of images, the trial core laboratory provided rigorous quality control of the image acquisition and analysis process (9) . The current investigation reports the complete, centrally analyzed echocardiographic findings from the high risk, operable patient population (Cohort A).
Randomization to SAVR or TAVR was stratified by feasibility of transapical or transfemoral access. Echocardiograms were obtained at baseline, and at 7 days, 30 days, 6 months, 1 year, and 2 years post procedure.
Echocardiography Core Laboratory Analysis
All echocardiograms were analyzed at an independent core lab which followed the American Society of Echocardiography (ASE) standards for echocardiography core laboratories.(10) Image acquisition quality was assured by: use of a detailed acquisition protocol, site qualification and training with quality feedback at regular intervals, and retraining of sites with unacceptable image quality. Image analysis quality was assured by: reader qualification, detailed analysis instructions, group and individual training, regular intra-and inter-observer variability testing, retraining and coaching when indicated (11) . All measurements and analyses were performed without knowledge of clinical or other laboratory data including prior echo results, group assignment, and timing of the assessment.
Reproducibility was determined on 649-1360 pair wise comparisons among readers for each of eight critical variables on 30 echoes (total number of comparisons =8,031). Intra-class correlation coefficients were 0.92-0.99 for physician over readers and 0.89-0.97 for sonographers. Kappa statistics for agreement for categorical variables calculated for physician readers were 0.56-0.85. Ventricular size and function and valvular function were measured according to previously published guidelines (7, 8, 12 ). An integrative, semi-quantitative approach was used to assess the severity of valvular regurgitation. Both qualitative (visual) and quantitative (biplane Simpson's method of discs) were used to report ejection fraction. Relative wall thickness (RWT) was calculated as 2x posterior wall thickness/LVED (RWTp) and also using the posterior wall thickness plus septal wall thickness as (septal wall thickness + posterior wall thickness)/LVED, or RWTm. Site-reported systolic annulus diameters were derived from long axis views. The effective orifice area (EOA) is calculated as the Doppler stroke volume ÷ aortic velocity time integral. The cover index was determined as (13) : [Prosthesis diameter -annular diameter] /prosthesis diameter. The severity of prosthesispatient mismatch was graded using EOA indexed to body surface area (7) with absence defined as > 0.85 cm 2 /m 2 , moderate ≥ 0.65 and ≤ 0.85 cm 2 /m 2 , and <0.65 cm 2 /m 2 .
Paravalvular regurgitation after TAVR/SAVR was graded in accordance with the ASE recommendations for native valves (14) and adoption of the 2009 prosthetic valve guidelines (7) with the following exception. Because of the eccentric, irregular, jet and the frequent noncylindrical 'spray' of the paravalvular jet contour, the parasternal short axis view(s) was weighted more heavily than other signals in providing an integrated assessment, as follows:
None -no regurgitant color flow
Trace -pinpoint jet in AV Mild -jet arc length is < 10% of the annulus circumference Moderate -jet arc length is 10-30% of the annulus circumference Severe -jet arc length is > 30% of the annulus circumference
Statistical Methods
Analysis is based on the actual valve implant patients who received and retained either a surgical or transcatheter valve, as this group is most appropriate for studying the echocardiographic measurements and outcomes. Intention to treat analysis (ITT) for evaluating trial endpoints has previously been reported (2, 5) . Because of the difficulty in imaging patients immediately following intervention, the first post-implant values are obtained from the first available value at discharge, 30 days or 6 months.
Categorical variables were compared using Fisher's exact test. Since regurgitation and prosthesis-patient mismatch are ordinal variables, comparisons involving these variables use the exact Jonckheere-Terpstra test. It should be noted that when one of the variables has two levels the test is equivalent to the exact Mann-Whitney U-test; where both have > two levels the use of the Jonckheere-Terpstra test is important. Continuous variables were presented as means (± SD) and compared using Student's t-test; comparisons with baseline values use the paired sample ttest. Survival curves for time-to-event variables were constructed using Kaplan-Meier estimates based on all available data and were compared using the log-rank test. To study the impact of risk factors on mortality, Cox proportional hazards regression was performed.
Imputation was not performed for missing baseline or first post-implant variables except in the multivariable models. The effect is that patients whose values are missing for a particular analysis are removed from that analysis.
Data are based on an extract date of February 13, 2012. All statistical analyses were performed in SAS ® , version 9.2.
Results
In the ITT TAVR arm there were 348 randomized patients; 344 were As Treated TAVR and 326 were Valve Implant of which 97 used transapical and 229 used transfemoral approaches. In the ITT SAVR arm there were 351 randomized patients; of these 313 were As Treated SAVR and 310 were Valve Implant ( Figure 1 ). Patients' baseline clinical demographics using the ITT populations are listed in Table 1 (online supplement). There were no statistically significant differences between the groups, except there were more patient with high creatinine in the TAVR group.
Baseline Echocardiographic Parameters
There were no baseline differences in LV size, geometry and function between as treated SAVR and TAVR groups ( Table 2 ). The two groups were similar in LVED, LV end-systolic dimensions (LVES), RWTp and RWTm, left ventricular mass, left ventricular mass index, LVDV, LVSV and left ventricular stroke volume as well as calculated ejection fraction.
Baseline valvular hemodynamics have previously been reported (4) and are summarized in Table 2 . There were no significant differences between SAVR and TAVR groups for baseline peak velocity, peak gradient, mean gradient, stroke volume (by any method) calculated aortic valve area, or aortic valve area index. There was no significant difference in the severity of mitral or aortic regurgitation.
Ventricular and Valvular Changes Immediately Following Intervention
In the TAVR cohort (Table 3 , online supplement), neither LVED nor LVDV changed immediately post intervention; however, LVES (p = 0.0005) and LVSV (p = 0.0016) were significantly smaller and ejection fraction higher (p < 0.0001). Peak and mean aortic valve gradients decreased (p < 0.0001) and EOA increased (p < 0.0001). There was a significant reduction in mitral regurgitation (p<0.0001) with no change in total aortic regurgitation (p = 0.649).
In the SAVR cohort there was a significant decrease in LVED, LVDV, LVES and LVSV immediately following intervention ( Table 3 , online supplement), associated with reduced stroke volume by 2DE (p<0.0001) and Doppler (p<0.0001), but no change in ejection fraction. Peak and mean aortic valve gradients decreased (p < 0.0001) and an increase in EOA (p < 0.0001). There was a significant reduction in both mitral regurgitation and aortic regurgitation (p < 0.0001). Table 4 compares TAVR and SAVR baseline and post-implant echocardiographic variables of ventricular size and function. TAVR as compared to SAVR had a significantly larger LVED up to 6 months following valve replacement, but not after 1 or 2 years of follow-up. LVDV showed inconsistent differences, neither LVES nor LVSV showed between group differences throughout follow-up. LV mass and LV mass index were larger in the TAVR patients at discharge, 6 months and 1 yr, but not at 2 yrs. The percent LV mass reduction was initially greater for the SAVR group, but was not significantly different after 6 months. RWTp and RWTm following valve replacement was initially higher for the SAVR group but progressively decreased for both groups.
Comparison of SAVR and TAVR
Although 2DE stroke volume showed inconsistent differences at various time points, Doppler stroke volume was significantly larger in TAVR patients up to 2 years at which time there was no significant difference. There was no significant between-group difference in ejection fraction throughout follow-up. Table 5 compares the baseline and post-implant echocardiographic variables of valvular function, for TAVR versus SAVR groups. Peak and mean transaortic gradients were significantly lower in the TAVR group for most time points. EOA and indexed EOA were significantly larger in TAVR at all follow-up time points. Prosthesis-patient mismatch was more common in SAVR throughout follow-up (Table 6 online supplement, and Figure 2 ). There were no significant differences in mitral regurgitation between TAVR and SAVR groups up to 2 years (Table 5, Figure 3 ).
TAVR patients had significantly more total aortic regurgitation at every post-implant time point compared to the SAVR cohort ( Table 5 and 7) . Mild, moderate or severe paravalvular aortic regurgitation (Table 8 online supplement, and Figure 4 ) was more common in the TAVR group at every follow-up time point (p <0.0001).
There were no cases of structural valve failure or migration of the valve after initially successful implantation in either group. Tables 4 and 5 show within-group changes over the 2 year follow-up period. Both groups showed a continuous reduction in RWT and left ventricular mass or left ventricular mass index over time. After an initial fall in Doppler stroke volume in the SAVR group, both groups showed significant increases in stroke volume over time. The TAVR group showed an immediate increase in ejection fraction following intervention with no change up to 2 years. The SAVR group showed no immediate increase in ejection fraction but a significant increase at 2years. Both groups showed immediate reduction in peak and mean transaortic gradients with slight further reductions over time. Both groups showed a sustained, stable increase in EOA and indexed EOA.
Within Group Changes over Time

Aortic Regurgitation
Following intervention, there was no significant change in total aortic regurgitation in the TAVR group, and an immediate reduction in the SAVR group followed by a slight increase in aortic regurgitation over time ( Table 5 ). Mitral regurgitation severity was reduced in both groups following intervention but showed a slight increase from immediate postintervention levels by 2 years.
In the TAVR group, paravalvular aortic regurgitation remained unchanged in 45.4% of patients, improved in 31.9% and worsened in 22.7% of patients. There were 7 patients who worsened from none/trace/mild to moderate following intervention. Conversely, there were 8 patients who improved from moderate to none/trace/mild. No patient developed new severe aortic regurgitation. There was no significant baseline patient clinical differences between patients with none/trace or ≥ mild paravalvular aortic regurgitation (Table 9 ) however, there were significant differences in echocardiographic measures of ventricular size and function. Patients with ≥ mild paravalvular aortic regurgitation had larger baseline measurements of aortic annular dimensions (p = 0.040), LVED (p =0.008), LVDV (p = 0.019), left ventricular mass (p = 0.003) and left ventricular mass index (p = 0.007). Baseline ejection fraction was also lower in the ≥ mild paravalvular aortic regurgitation group. A greater number of patients with ≥ mild paravalvular aortic regurgitation had low stroke volume (≤ 35 ml/m 2 ) at baseline. There were no significant differences in baseline gradients or valve area. There was no impact of the prosthesis size on severity of total aortic regurgitation (none, trace, mild, moderate or severe) (p = 0.38, not shown) or paravalvular aortic regurgitation following TAVR (Table 9 ).
Following TAVR, patients with ≥ mild paravalvular aortic regurgitation had larger first postimplant LVED (p =0.009), LVDV (p = 0.003), LV mass (p = 0.001) and LV mass index (p = 0.007). There was no difference in first post-implant ejection fraction, transaortic gradients, EOA, prosthesis-patient mismatch or implanted valve size. There was a higher frequency of low cover index (< 8%) in patients with ≥ mild paravalvular aortic regurgitation (p = 0.012). There was a significantly higher 2DE and Doppler stroke volume in the ≥ mild paravalvular aortic regurgitation group.
Echocardiographic Variables Associated with Outcome
Univariate echocardiographic determinants of mortality in the TAVR group were evaluated ( Table 10 ). The only baseline echocardiographic univariate predictor of death in the TAVR group was baseline peak gradient (HR [95%CI] = 0.94 [0.90, 0.99] per 5 mmHg increase, p = 0.010). After implantation, there were a number of echocardiographic univariate predictors of death in the TAVR group, the strongest of which was ≥ mild paravalvular aortic regurgitation (HR [95%CI] = 2.11 [1.43, 3.10], p = 0.0002). Other post-TAVR predictors of mortality include: larger LVDV, LVSV and indexed EOA, and lower ejection fraction. The presence of prosthesis-patient mismatch (indexed EOA<0.85 cm 2 /m 2 ) was a predictor of decreased mortality (HR [95%CI] = 0.736 [0.57, 0.96], p = 0.024).
There were many baseline univariate echocardiographic determinants of mortality in the SAVR group (Table 11) , the strongest of which was mitral regurgitation (HR [95%CI] = 1.49[1.17, 1.90] per 1 grade, p = 0.001). After valve replacement, the strongest univariate echocardiographic predictors of death were the presence of low stroke volume (≤ 35 ml/m 2 ) (HR [95%CI] = 1.97 [1.16, 3.33], p = 0012) and prosthesis-patient mismatch (HR [95%CI] = 1.43[1.11, 1.84], p = 0.005). Other post-SAVR predictors of mortality include: smaller LVDV, LVSV, EOA, and stroke volume.
Discussion
Cohort A of the PARTNER trial is the first large randomized trial showing comparable outcomes of SAVR and TAVR in high risk, operable patients with severe symptomatic aortic stenosis (4) . The present study reports the centrally analyzed echocardiographic data comparing SAVR and TAVR, which documents early and sustained hemodynamic improvements with both therapies, and freedom from structural valve deterioration, while highlighting the differences in therapeutic groups, and presenting echocardiographic determinants of outcome.
Valve Performance
Improvements in valve area and mean gradients are sustained over the two year interval reported with no evidence of stent recoil in the TAVR group. No structural valve dysfunction was found out to 2 years in either arm of this study. The current study thus highlights the twoyear durability of the Edwards SAPIEN balloon-expandable valve.
Ventricular remodeling and function
Following valve replacement, there is substantial ventricular remodeling with reduction in RWT and left ventricular mass in both groups. The SAVR group had more absolute LV mass regression early however there was no difference in mass regression rates over the follow-up period between SAVR and TAVR. Factors other than valve area may adversely influence left ventricular remodeling including: more aortic regurgitation (in the TAVR population), or concomitant surgical procedures (MV repair/replacement or coronary bypass performed as protocol violations in the SAVR population).
Ejection fraction improves early following TAVR and later during follow-up in the SAVR group with no significant difference by 2 years. Because LVED, LVES and mitral regurgitation are not significantly different between groups, the larger stroke volumes in the TAVR group support the qualitative finding of greater aortic regurgitation. Other factors which could influence LV remodeling (i.e.: hypertension, renal dysfunction, sex) and ventricular function warrant further study.
Factors Associated with Outcome
The TAVR and SAVR groups had different univariate factors associated with outcome. In the TAVR group only baseline low peak gradients, possibly in the setting of low stroke volume, predicted worse outcome. Post-TAVR, larger LV volumes (either systolic or diastolic) and lower EF determined worse outcome; how this may be related to aortic regurgitation is unknown. In the SAVR group, baseline or post-SAVR small LVEDV and low stroke volume, are associated with increased mortality. The strongest predictor of mortality was baseline severity of mitral regurgitation. Some patients (6) had concomitant mitral surgery (a protocol violation) and how this may influence outcomes require further investigation.
Similar to previous studies (25) , our study confirms that prosthesis-patient mismatch has a negative effect on survival in the SAVR population. Also similar to prior studies (15) , indexed EOA in the TAVR groups is larger compared to the SAVR group despite comparable annular dimensions. Counter-intuitively, univariate analysis of the TAVR group had a lower mortality in the presence of prosthesis-patient mismatch. This finding may be driven by body size, since in the TAVR cohort; body mass index was also associated with lower mortality (Table 10) . Conversely, this finding may also be driven by a population of patients with a small annulus; patients with a small aortic annulus have better outcomes with TAVR compared to SAVR (16, 17) . In addition, a small annulus in the TAVR population has been associated with less paravalvular aortic regurgitation (13) . Further multivariable modeling should be performed.
Aortic Regurgitation
Recent surgical studies suggest paravalvular regurgitation following SAVR occurs in 10-48% (18-23) and even mild paravalvular regurgitation has a negative impact on survival (24) . The current study confirms a high incidence of aortic regurgitation in the SAVR group (50%) however only 14% have ≥ mild paravalvular aortic regurgitation.
Our study supports other studies (25) (26) (27) (28) showing a significant relationship between mortality and paravalvular aortic regurgitation in TAVR patients. Despite the inherent limitations of the current grading method for paravalvular regurgitation, it has been shown to predict outcomes (5) which provides indirect validation. Further validation of this grading scheme against other quantitative assessments of severity of regurgitation should be performed. Finally, it is possible that differences in the baseline characteristics between groups with paravalvular aortic regurgitation may have contributed to the increased mortality.
Limitations
We used the site-specified systolic annular measurement since: 1) most were from intraprocedural transesophageal echocardiograms and likely more accurate than transthoracic measurements and 2) the measurement was performed in systole (whereas as per previously published guidelines (12) the ECL performed aorta measurements in diastole). In the PARTNER trial, a systolic, sagittal plane systolic annulus was used for sizing the transcatheter heart valve. Whenever possible, we evaluated paired echocardiographic data; however, longitudinal differences between groups with high mortality rates may introduce survivorship bias. Finally, echocardiographic measurements are dependent on image quality as well as inter-and intraobserver variability. Use of an echocardiographic Core Laboratory should limit this variability as has been demonstrated previously for the PARTNER trial (9) however limited echocardiographic measurability may introduce another form of bias. In addition, a large number of variable comparisons have been made in the manuscript, and no adjustment has been made for the multiple comparisons.
For the "first post-implant" measurement discharge or 30 day values were used in 90-96% of ventricular size and function measurements, and 99% of Doppler measurements; 6 month data was used rarely.
The limitations of paravalvular aortic regurgitation grading have been discussed but remain a significant issue for both surgical and transcatheter valves. It is important to note that the circumferential extent grading scheme used differs slightly from the upper cut point of 20% for moderate paravalvular regurgitation recommended by the 2009 ASE/EAE guidelines (7) which were published after the PARTNER analysis plan was established.
Advanced echo techniques, such as three-dimensional color Doppler echocardiography or quantitative methods, as well as intra-procedural studies were not evaluated.
Conclusions
This study is the first to use centrally analyzed echocardiographic data to compare the structural and hemodynamic results in high-risk patients with symptomatic severe aortic stenosis randomized to SAVR or TAVR. Immediately following valve replacement, both groups showed a significant reduction in transaortic gradients and increase in EOA with similar LV mass regression and remodeling over time. However, indexed EOA was consistently higher and prosthesis-patient mismatch lower in the TAVR group throughout the follow-up period. The intermediate-term durability of the Edwards-SAPIEN valve is comparable to SAVR. Survival was strongly affected by low stroke volume and prosthesispatient mismatch in the SAVR cohort and post-intervention aortic regurgitation in the TAVR cohort. A complete understanding of these differences may allow future refinement in patient selection.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Flow chart of high risk Placement of Aortic Transcatheter (PARTNER) Valves trial. Figure  1A shows the flow chart of patient randomization and follow-up for Cohort A of the PARTNER trial. Figure 1B outlines the intention-to-treat (ITT) and as-treated patient population of Cohort A. Paravalvular aortic regurgitation incidence. The incidence of paravalvular aortic regurgitation in the TAVR versus SAVR patient populations is shown at various follow-up time points with p-values for between group differences noted. There is a significantly more aortic regurgitation in the TAVR group at every time point. Post-intervention Echocardiographic Findings for Ventricular Structure and Function in the TAVR vs. SAVR (Valve Implant Population) Mitral Regurgitation ** (n = 152) 1.8 ± 0.9 (n = 153) 2.0 ± 0.8 0.0791 
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